Use of psychedelic treatments in psychiatric clinical practice: an EPA policy paper
European Psychiatry January 1, 2025 Marianne Destoop, Pavel Mohr, Florence Butlen‐ducuing et al. 7 citations
The European Psychiatric Association (EPA) acknowledges the therapeutic potential of psychedelic substances for mental disorders, such as psilocybin for depression, which are nearing regulatory approval in the US and Europe. This policy paper highlights both the benefits and challenges of psychedelic treatments, emphasizing the importance of psychosocial components and ethical, professional aspects for real-world implementation. Four recommendations are formulated to guide further research and clinical integration, aiming for safe, ethical, and equitable access for all patients who may benefit.